pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Washington University School of Medicine

updated 5mo ago
community read0 votes

🐶 often sniffed alongside

top 3
  • tagOncology5 co-mentions · 2 sources
  • drugSCEMBLIX1 co-mentions · 1 sources
  • drugasciminib hydrochloride1 co-mentions · 1 sources
pipeline
0
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • N/ARESTORE Declined Livers Studycompletedn=24
  • phase2Cabozantinib in High Grade Neuroendocrine Neoplasmsactive not recruitingn=35
  • phase1Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinomarecruitingn=24
  • phase1Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcomasuspendedn=18
  • —Ovarian-Sparing Adaptive Radiotherapy in Young Adult Womencompletedn=10
  • phase2Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinomacompletedn=43
  • phase2Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)not yet recruitingn=45
  • N/ACholine to Improve Malnutrition and Enhance Cognitionactive not recruitingn=1,500
🐶 Hiring Signal
No open roles indexed yet — view Washington University School of Medicine jobs →

News

  • With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
    Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of…
    fiercebiotech · 12d ago
  • Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
    Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
    biopharma_dive · 1mo ago
  • Transplants extended survival for patients whose stage 4 lung cancer hadn’t spread, study says
    Lung cancer patients hadn't been seen as candidates for organ transplant. Now a study finds patients did well.
    stat · 2mo ago
  • Half of states sue over Medicaid work requirements
    FDA peptide panelists, a new study on Covid and flu shots, and more health news from Morning Rounds
    stat · 3mo ago
  • Study highlights influence of socioeconomic status on children’s brain development
    A new study found that the leading environmental factor influencing brain structure and function is the socioeconomic status of a child's family.
    stat · 3mo ago
identifiers
source
globaldata
mentioned in
5news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?